Venetoclax-based therapy is effective in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but tumor lysis syndrome (TLS) risk necessitates a resource-intensive five-week dose ramp-up with intravenous hydration, frequent laboratory monitoring, and clinic-based observation, creating logistical barriers particularly in community settings. We conducted a single-center, IRB-approved retrospective pilot study of 30 patients with CLL/SLL who underwent a cytoreduction-adapted, IV-free outpatient venetoclax ramp-up with reduced laboratory monitoring between 2023 and 2026. All patients received cytoreductive therapy—predominantly single-agent BTKi—and met protocol-defined low-tumor-burden criteria (ALC < 20 × 109/L, lymph nodes < 5 cm, no splenomegaly, CrCl > 45 mL/min) before venetoclax initiation. Venetoclax was self-administered at home with laboratory monitoring reduced to a single approximately 12-h post-dose assessment per dose-escalation week. Median age was 71 years; 80% had received ≥2 prior therapy lines, and 37% had high-risk cytogenetics. Monitoring compliance was 100%. No laboratory or clinical TLS, IV hydration, hospitalizations, dose interruptions, treatment discontinuations, or deaths occurred during ramp-up. These pilot data support the feasibility and early safety of simplified outpatient venetoclax initiation in adequately cytoreduced patients and warrant prospective multicenter validation.
Classic Hairy Cell Leukemia (cHCL) and related conditions are rare, indolent B-cell malignancies characterized by distinctive morphological, immunophenotypic, and molecular features. Over the past decade, major advances in understanding the pathophysiology and molecular underpinnings have reshaped diagnostic and therapeutic approaches. This review synthesizes current knowledge on the cellular origins and signaling pathways that drive cHCL and Hairy Cell Variant (HCL-v)/splenic B-cell lymphoma/leukemia (SBLPN) and other molecular aberrations in disease pathogenesis. We discuss evolving diagnostic modalities, including flow cytometry, immunohistochemistry, and next-generation sequencing, that enhance diagnostic precision and disease monitoring. Additionally, we examine established and emerging therapeutic strategies—from purine nucleoside analogs (PNA) to targeted inhibitors and immunotherapies—that have significantly improved patient outcomes while highlighting challenges such as relapse and treatment resistance. By integrating insights from molecular biology and clinical practice, this review aims to provide a comprehensive understanding of cHCL and related disorders.